Prescription-price sticker shock: Will federal lawmakers intervene?

Modern Healthcare (complimentary online subscription): As more details emerge chronicling the lengths some pharmaceutical firms have gone to to set a premium price on their products, stakeholders are split on whether the government will act on the crisis.Drug companies have remained in the spotlight since Turing Pharmaceuticals and its CEO, Martin Shkreli, first announced and then backed away from plans to raise the price of Daraprim.

Read article